Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018-2020.
Rohan KhazanchiSamuel PowersAmy KilleleaAndrew StrumpfTim HornAuntré HampKathleen A McManusPublished in: Journal of pharmaceutical policy and practice (2023)
QHP coverage of STRs is heterogeneous across the US. While coverage of BIC/FTC/TAF increased over time, many QHPs in EHE priority jurisdictions required coinsurance. Access to new ART regimens may be slowed by delayed QHP coverage and benefit design.